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Abstract
The emergence of highly chloroquine (CQ) resistant P. vivax in Southeast Asia has created an urgent need for an improved
understanding of the mechanisms of drug resistance in these parasites, the development of robust tools for defining the
spread of resistance, and the discovery of new antimalarial agents. The ex vivo Schizont Maturation Test (SMT), originally
developed for the study of P. falciparum, has been modified for P. vivax. We retrospectively analysed the results from 760
parasite isolates assessed by the modified SMT to investigate the relationship between parasite growth dynamics and
parasite susceptibility to antimalarial drugs. Previous observations of the stage-specific activity of CQ against P. vivax were
confirmed, and shown to have profound consequences for interpretation of the assay. Using a nonlinear model we show
increased duration of the assay and a higher proportion of ring stages in the initial blood sample were associated with
decreased effective concentration (EC50) values of CQ, and identify a threshold where these associations no longer hold.
Thus, starting composition of parasites in the SMT and duration of the assay can have a profound effect on the calculated
EC50 for CQ. Our findings indicate that EC50 values from assays with a duration less than 34 hours do not truly reflect the
sensitivity of the parasite to CQ, nor an assay where the proportion of ring stage parasites at the start of the assay does not
exceed 66%. Application of this threshold modelling approach suggests that similar issues may occur for susceptibility
testing of amodiaquine and mefloquine. The statistical methodology which has been developed also provides a novel
means of detecting stage-specific drug activity for new antimalarials.
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Introduction
Malaria continues to pose a significant threat to human health
globally. Currently, as many as 2.6 billion people are at risk of P.
vivax infection, with an estimated 72–390 million cases per year
[1,2]. Historically, malaria research has focussed on P. falciparum,
due to its reputation as the most lethal human malaria parasite.
Although P. vivax is less pathogenic than P. falciparum, it still poses a
serious public health burden and is being increasingly recognised
as a cause of severe and fatal disease, particularly in children and
pregnant women [2,3].
A number of recent publications have highlighted the increasing
recognition of the clinical importance of P. vivax and the renewed
emphasis placed on research into this species [2,4,5,6]. Further, the
emergence of highly chloroquine (CQ) resistant P. vivax in Southeast
Asia (CQ remains a front-line treatment for vivax malaria as it is
affordable, well tolerated and safe, and its long half-life ensures
protection from early relapses [7,8]) has created an urgent need for
an improved understanding of the mechanisms of drug resistance in
these parasites, the development of robust tools for defining the
spread of resistance, and the discovery of new antimalarial agents.
To glean insights into the development of resistance in P. vivax, a
modified form of the ex vivo Schizont Maturation Test (SMT) has
been developed and applied to fresh isolates directly from patients
[9,10,11,12].
The central tenant of the SMT is that drug activity on susceptible
parasites will completely stop or slow the growth in a dose-
dependent manner, with reduced susceptibility being manifest by
an ability of parasites to mature to schizont stages in the presence of
higher concentrations of drug. The standard assay is conducted for
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30 hours, the time required for parasites to reach maturation
without drug, and the proportion of schizonts at the conclusion of
the assay is used as an indicator of parasite maturation.
The SMT was initially developed for testing drug susceptibility
in P. falciparum [13,14], where almost all parasites in the peripheral
circulation are at the immature ring stage. However, in infections
due to non-falciparum species, trophozoite and schizont stages are
commonly present in the peripheral circulation. To accommodate
this, a modified SMT has been developed in which the control
wells are monitored until the number of schizonts exceeds 40% of
parasites prior to harvest (i.e., assays are conducted for variable
lengths of time) [15].
For the results of the SMT to be valid, a sample, irrespective of
the drug resistance phenotype of the parasites, must have had
sufficient exposure to the drug to affect a response. The diversity in
parasite life cycle stages in P. vivax infections creates a significant
confounding factor, particularly since there is an apparent marked
variation of drug susceptibility in different erythrocytic life cycle
stages. In previous work, it has been demonstrated that the
trophozoite stages of P. vivax are almost completely resistant to
CQ, and continue to mature no matter how high the concentra-
tion of drug [15,16]. It follows that, if a drug only acts on ring
stage parasites, but the sample contains a majority of trophozoites
and schizonts, the parasite is likely to be erroneously categorised as
resistant simply because there were no susceptible life cycle stages
present in the assay.
In this study we develop a statistical methodology to identify
stage specific drug activity in the SMT. We use CQ against P. vivax
as a case study and demonstrate that stage specific drug activity
has profound consequences for the interpretation of SMT results.
We also examine stage-specific drug effects for other commonly
used drugs and simulate the growth dynamics of P. vivax parasites
within the SMT to provide recommendations on how to improve
the reliability of SMT results.
Methods
Ethics Statement
Ethical approval for the collection of blood samples for drug
susceptibility testing was obtained from the ethics committees of
the National Institute of Health Research and Development,
Ministry of Health (Jakarta, Indonesia), and the Human Research
Ethics Committee of NT Department of Health & Families and
Menzies School of Health Research (Darwin, Australia). Written
informed consent was obtained from adult patients and parents
and/or guardians of enrolled children.
Data collection and ex vivo drug susceptibility testing
Blood samples were collected from patients attending outpatient
clinics in Timika, Papua Province, Indonesia, as previously
described [15]. Only patients infected with a single species of
Plasmodia were included in the study; the majority of samples
contained P. vivax or P. falciparum, although a limited number of P.
malariae and P. ovale isolates were also available [17].
SMTs were conducted on these samples following World
Health Organisation guidelines for drug susceptibility testing [18],
with modifications developed to aid the application of the test to P.
vivax [15]. Venous blood (5 mL) was collected by venipuncture,
and after removal of host white blood cells using a CF11 column,
800 mL of packed infected red blood cells (IRBC) were used for the
SMT. Assays conducted for up to 7 drugs: CQ, artesunate,
amodiaquine, lumefantrine, mefloquine, piperaquine and pyro-
naridine [15].
The proportion of parasite life cycle stages (i.e., rings,
trophozoites and schizonts, as defined by Russell et al [12,15]) in
each isolate was assessed at 0 hours, 24 hours, and then at non-
uniform times until 40% of the parasites in the control well
reached mature schizonts. At this point, the assay was terminated,
and wells under serial drug concentrations were harvested. The
proportion of parasites in each stage of the erythrocytic cycle at
time of harvest was reported for each drug concentration, as was
the duration of the assay.
Dose Response Modelling
The estimated drug response (R) of each isolate was derived
from the ratio between the proportion of schizonts at harvest in the
treatment well compared to that in the control well. Only data
satisfying the following criteria were included in the dose response
modelling:
1. R,1.5 for all drug concentrations,
2. R.0 for the lowest drug concentrations,
3. R,0.5 for at least one drug concentration.
The sigmoid Emax dose-response curve (equation 1) was fitted to
all available data simultaneously, with mixed-effects modelling
used for CQ data.
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Rij represents the drug mediated growth inhibition response (the
ratio between the proportion of schizonts at harvest in the
treatment well compared to the control well) for the ith isolate at
the jth concentration, cij represents the drug concentration. Emax
and E0 represent the maxima and minima of the dose response
curve and c the slope of this curve. The EC50 value represents the
effective concentration at which 50% of the parasite population
Author Summary
The schizont maturation test (SMT) was developed to
monitor drug resistance in malaria parasites. The SMT
examines differences in the rate of parasite development
when exposed to different drug concentrations, providing
an estimate of drug efficacy. While the assay is effective
when examining resistance in Plasmodium falciparum,
there are concerns regarding its suitability for testing
other malaria species, particularly if the drug only targets
particular life-cycle stages of the parasite. Blood samples
taken from Plasmodium vivax infected individuals exhibit
significant heterogeneity in the parasite life-cycle stages
present. If a drug targets the early stage parasites, but only
late stage parasites are present in the sample, the test will
show an erroneously high degree of resistance. In this
study, we estimate thresholds which can be used to
identify when test results can be considered accurate
should the drug being tested only affect specific life stages
of the parasites. Chloroquine is used as a case study but
the method developed also allows the identification of
stage-specific activity in other malarial drugs in P. vivax.
For field researchers, this threshold modelling approach
will allow for increased confidence in the reliability of P.
vivax resistance results and provides a novel means of
detecting stage-specific drug activity for new antimalarials
Stage-Specific Drug Activity in Plasmodium vivax
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exhibit a response to the drug. Inter-isolate variability was
included for Emax, EC50 and c. The drug plate batch was also
incorporated as a random effect, to control for batch-to-batch
variability. Predicted values for EC50 for each isolate were
calculated from Empirical Bayes estimates.
EC50 values for parasite samples collected from April 2004 and
May 2007 have previously been reported (Russell 2008). However
the methodology used to calculate EC50 for CQ differs between
the previous report and the current study due to the use of mixed-
effects modelling.
Statistical analysis
For each of the seven drugs tested, linear regression models
were used to characterise the relationship between the EC50 values
derived for each isolate and the following independent variables:
assay duration, the proportion of rings at 0 hours, and delay
between venepuncture and assay. The EC50 values were not
normally distributed, therefore ln(EC50) was used as the dependent
variable.
Where a relationship between one of the independent variables
and ln(EC50) was found a non-linear threshold model was
constructed to determine the threshold at which the association
ceased to exist (Equation 2).
EC50~bz Durationvcð Þ  a  Duration{cð Þ, ð2Þ
a represents the rate of decline in EC50 when the duration of the
assay is less than the threshold, b the mean EC50 values for samples
where the duration exceeds the threshold, and c the threshold. A
threshold model was preferred over other non-linear models due
to the greater interpretability of parameters.
A threshold model of the same form was also fitted to define the
relationship between the proportion of rings at time 0 and EC50.
The threshold models were fitted to the data using nonlinear
regression.
Characterising the duration of the erythrocytic cycle
A simulation approach was used to estimate the duration of
each stage of the erythrocytic life cycle in both P. vivax and P.
falciparum. Estimates were also made of stage durations using the
limited data available for P. malariae and P. ovale to validate the
methodology. Poisson distributions were selected to represent the
duration of each stage, as random deviates produced by sampling
the distribution are always positive, and the parameters of the
distributions allow for biologically meaningful interpretation. We
assumed the duration of each stage could be drawn from a
probability distribution, and estimate the mean of each Poisson
distribution (l).
One hundred simulations of the growth dynamics within a
culture well, each containing 200 parasites, were conducted. It was
assumed each parasite began life as a ring, transitioned to a
trophozoite, then to a schizont. The length of time spent in each
stage was determined by sampling from the relevant probability
distribution. At selected time points, the proportion of parasites in
each stage was calculated. As parasites completed the schizont
stage, they were assumed to die, and subsequently, proportions
were calculated based only on the remaining surviving parasites.
A systematic search of the parameter space for the mean
duration in each life cycle stage (l) was conducted to determine the
optimal values for each Poisson distribution. The mean model fit
from three simulation experiments (totalling 300 simulations) for
each combination of parameters was used and the search
examined potential parameters in increments of 0.5 hours.
The optimal fit was determined by minimising the sums-of-
squares between the simulation results and data on proportion of
parasite at each life cycle stage from the control wells, for a subset
of the original field samples. The subset of field samples used had
1) 100% rings at 0 hours, 2) data for at least 3 time points, and 3)
an assay duration .42 hours. This subset was used to ensure only
samples with young ring stage parasites were included in the fitting
process. A penalty equivalent to a difference of 20 between data
and simulation results was applied for any later time points where
the death of the entire simulated parasite population meant that
no direct comparison could be made to the data.
All statistical analyses and simulations were conducted using the
R statistical computing software package [19].
Results
Description of initial samples (at 0 hours)
SMT results for parasites sourced from 784 patients with single-
species infections of either P. vivax (n=345) or P. falciparum (n=439)
were analysed; 289 (84%) P. vivax and 331 (75%) P. falciparum
isolates met the inclusion criteria for statistical analysis. Among
these, 141 P. vivax (49%) and 216 P. falciparum (65%) isolates
reached the 40% schizont threshold at harvest. The time between
venepuncture and start of the assay (the ‘delay’) was significantly
correlated with the duration of the assay for isolates of P. falciparum
(correlation co-efficient (r) =20.211, p,0.001), but not P. vivax
(r=20.065, p=0.226).
There was a significantly higher mean proportion of ring stage
parasites in samples at the start of the assay (0 hours) for P.
falciparum (0.922) compared to P. vivax (0.588) (Wilcoxon rank sum test,
p,0.001). 87.5% (189/216) of P. falciparum isolates contained
100% ring stage parasites at 0 hours, compared to only 2.8% (4/
141) of P. vivax isolates.
Predictors of CQ susceptibility
There was a significant negative association between the CQ
assay duration (hours) and the ln (EC50) values for P. vivax
(r2=0.219, p,0.001; Figure 1a). A similar, but weaker relationship
was observed for P. falciparum (r2=0.097, p,0.001; Figure 1b).
Figure 1 suggests some bimodality in the distribution of results, but
this is predominantly due to the lack of sampling between,32 and
40 hours. The proportion of rings at the start of the assay was also
significantly negatively associated with the ln(EC50) values for both
P. vivax (r2=0.245, p,0.001) and P. falciparum isolates (r2=0.206,
p,0.001; Figure 2). In both species there was a significant negative
correlation between the proportion of rings at the onset of assay
and assay duration (r2=0.621, p,0.001; r2=0.185, p,0.001, for
P. vivax and P. falciparum, respectively).
The threshold model for assay duration was successfully fit to
the P. vivax data (Figure 3, Table 1). The threshold value, c,
represents the point at which the assay duration was no longer
significantly associated with estimates of EC50. We interpret this
threshold as the point at which assay duration was sufficiently long
to guarantee that the target parasite stage/s were present and
exposed to the drug. Although there was a relationship between
assay duration and EC50 for P. falciparum we were unable to fit a
threshold model as fitting procedures did not identify an
appropriate non-linear model and associated threshold point.
A threshold model to determine the relationship between the
initial proportion of rings and the EC50 was also only possible for
P. vivax; we were unable to fit a threshold model to the P.
falciparum data. For P. vivax the proportion of rings at the onset of
assay was found to have a significant non-linear relationship with
EC50 (Figure 4; Table 2). Samples with less than 65% ring stage
Stage-Specific Drug Activity in Plasmodium vivax
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parasites at time 0 had higher and more variable EC50 values
than those isolates with a greater proportion of ring stage
parasites.
Comparisons with other drugs
Of the six other drugs tested, threshold models were successfully
fitted to data for amodiaquine and mefloquine in P. vivax.
Confidence intervals around the estimated threshold points
showed distinct overlap, suggesting no significant differences
between the two drugs, or CQ (Table 3).
Characterising the duration of the erythrocytic cycle
In the simulations of the growth dynamics under ex vivo assay
conditions, the l parameter for the Poisson distributions
represented the duration of each parasite life cycle stage in P.
vivax. The mean l was 19.1 hours (95% CI 11, 29) for rings,
23.1 hours (95% CI 11, 36) for trophozoites, and 2.2 hours (95%
CI 0, 7) for the schizonts. The total duration of the P. vivax
erythrocytic cycle was estimated as 44.5 hours (95% CI 29, 62).
Similar simulations of P. falciparum growth gave mean estimates of
the l parameter of 23.3 hours (95% CI 14, 33) for ring stage
parasites, 21.4 hours (95% CI 11, 33) for trophozoites, and
3.7 hours (95% CI 0, 10) for schizonts; estimates produce a total
duration of 48.4 hours (95% CI 32, 66). These estimates of an ex
vivo life cycle do not include the age of the rings before the start of
the assay and the growth time of schizonts after the end of the
assay, thus the true life cycle is expected to be longer than
reported.
To validate the methodology, the growth dynamics of a small
number of SMT results were also simulated for P. malariae (n = 39)
and P. ovale (n = 13) isolates. The total duration of the erythrocytic
cycle was estimated to be 75.6 hours (95% CI 59, 93) in P. malariae
and 53.9 hours (95% CI 34, 79) in P. ovale.
Discussion
Despite being developed initially for P. falciparum parasites, the
Schizont Maturation Test (SMT) has seen considerable use in
testing drug susceptibility of P. vivax. However, little consideration
has previously been given to whether the application of the SMT
to P. vivax is appropriate. In this study, we demonstrate that the
Figure 1. Relationship between assay duration and ln(EC50).
The figure depicts relationships for (A) P. vivax (n = 141) and (B) P.
falciparum (n = 216).
doi:10.1371/journal.pntd.0001772.g001
Figure 2. Relationship between the proportion of ring stage
parasites at start of assay (0 hours) and ln(EC50). The figure
depicts relationships for (A) P. vivax and (B) P. falciparum.
doi:10.1371/journal.pntd.0001772.g002
Figure 3. Threshold modelling results for the relationship
between assay duration and estimated CQ EC50 values in P.
vivax.
doi:10.1371/journal.pntd.0001772.g003
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stage-specific dynamics of drug activity may impact on the validity
of SMT results. If a particular drug targets ring stage parasites, but
is tested in an isolate predominantly containing mature stage
parasites, the drug will appear to be ineffective, resulting in an
overestimate of resistance. Assay duration and the proportion of
rings in the initial sample both provide proxy indicators of the
likelihood that early stage parasites will be exposed to drugs.
Previous experimental work has identified that trophozoite stage P.
vivax parasites are insensitive to CQ [15,16]; our results support
this finding. We apply statistical analysis techniques to show that
the heterogeneity of erythrocytic life cycle stages present in
peripheral blood samples taken from patients infected with P. vivax
necessitates additional criteria be applied to the SMT to ensure the
validity of the results.
The significant negative relationship between the time of
venepuncture and start of the SMT and duration of the SMT
for P. falciparum was not unexpected. The onset of fever is usually
associated with the start of a new erythrocytic cycle, meaning the
sum of the time elapsed between establishment of the SMT and
SMT duration will be more indicative of total duration of the
erythrocytic cycle than the SMT duration alone. Hence, parasites
which have a delay between venepuncture and start of SMT will
enter the SMT in a more advanced state, requiring less time to
develop to 40% schizonts. This effect is most likely more dominant
in P. falciparum samples due to the high synchronicity in parasites
when obtained from the patient, compared to P. vivax.
For both P. vivax and P. falciparum isolates, there were significant
negative relationships between the duration of the assay and
estimated EC50 values (i.e., short duration assays were associated
with reduced susceptibility to drugs). There are a number of
possible explanations for these results, none of which is mutually
exclusive and all of which are specific to the drug/parasite
combination:
1. Later stage parasites are more tolerant to the drug then ring
stage parasites; the higher the proportion of ring stage parasites
the lower the EC50,
2. The drug effect is cumulative over time which results in longer
exposure times having a greater relative effect for the same
drug concentration,
3. Resistant parasites grow faster.
When stage-specific drug activity is a consideration, as with CQ
against P. vivax [15,16], we hypothesised that samples more
advanced in their development, as characterised by short assay
duration or a low proportion of ring stage parasites in the initial
blood sample, would appear to be less susceptible to a drug
because a significant number of parasites present in the assay had
developed beyond the target stage. Support for this hypothesis is
provided by the threshold modelling. While the linear models we
have described are appropriate for the P. falciparum SMTs,
examination of the trends in P. vivax suggest a distinctly non-
linear pattern for some drugs, including CQ. The threshold
modelling indicates that the EC50 for CQ in P. vivax parasites
stabilises once the sample has been exposed to the drug for at least
33.7 hours (CI 28.2, 39.3). The simulation modelling of parasite
development time suggests that P. vivax parasites spend an average
of 25.3 hours as trophozoites and schizonts before termination of
the assay. If the SMT is terminated when the control well reaches
40% schizonts, and this occurs after 33.7 hours (mean duration
threshold), it follows that the SMT must have exposed sufficient
ring stage parasites to the drug, resulting in EC50 reaching its
minimum. Combining the results from the threshold and life cycle
modelling, an assay lasting 33.7 hours will have exposed 86.5% of
the parasites to CQ for at least one hour at ring stage. Using the
upper 95% confidence limit for mean assay duration, a more
conservative threshold estimate of 39 hours, we can predict that
95% of the parasites were exposed to CQ for at least 2 hours at
ring stage. We propose that this threshold represents the duration
of the assay which is sufficient to guarantee that a significant
proportion of the ring stage P. vivax parasites have been exposed to
the drug (i.e. there is no longer any association between duration
and EC50). Assay durations shorter than this threshold expose a
greater proportion of tolerant mature stage parasites to the drug,
Table 1. Parameter estimates for threshold modelling of the relationship between assay duration and CQ EC50 in P. vivax.
Parameter Estimate 95% Confidence Intervals P-value
Lower Upper
Threshold (c, in hours) 33.73 28.15 39.31 ,0.001
Change in EC50 per increase of one hour assay
duration when assay duration,c (a)
282.01 2131.69 232.33 0.002
Mean EC50 when duration.c (b, in nmols/l) 141.91 219.05 302.87 0.086
doi:10.1371/journal.pntd.0001772.t001
Figure 4. Threshold modelling results for the relationship
between the proportion of rings in the initial sample and
estimated CQ EC50 values in P. vivax.
doi:10.1371/journal.pntd.0001772.g004
Stage-Specific Drug Activity in Plasmodium vivax
www.plosntds.org 5 August 2012 | Volume 6 | Issue 8 | e1772
and thus the EC50 values derived from these samples will be
artificially elevated.
Similar dynamics are apparent when examining the composi-
tion of the initial blood samples. The disparity in the degree of
developmental stage heterogeneity in the initial samples between
P. vivax and P. falciparum is striking. P. falciparum isolates are
markedly more synchronous, presumably because the mature
stages (trophozoites and schizonts) are sequestered in deep tissues
and organs, rather than in the peripheral circulation. Nearly all P.
falciparum samples contain only rings, and are, therefore, ideal for
SMT. In contrast, P. vivax isolates tend to show significantly
greater heterogeneity in the life cycle stages, with trophozoites and
schizonts regularly occurring. The presence of these advanced
stages at the onset of SMT makes the interpretation of drug
susceptibility results more difficult. Our modelling suggests that the
initial sample should contain a minimum of 66% ring stage
parasites, preferably .90% ring stage parasites (upper 95%
confidence interval of the threshold parameter), to ensure the
target life cycle stages are sufficiently present in a sample.
However, this significantly reduces the number of samples from
which drug sensitivity data can be obtained potentially introducing
a sampling bias. It should be noted that, by selecting only those
samples that achieve 40% schizonts, we also introduce bias against
those parasites that do not grow well in culture.
Processes for synchronising parasitemia have also been
proposed as a means of decreasing stage heterogeneity of
Plasmodium isolates for ex vivo characterisation [20,21]. Although
such methods may have utility and permit testing of some field
isolates that would otherwise be excluded from testing, the
removal of mature trophozoite parasites inevitably results in a
reduction in parasite count, which is itself another important
parameter for reliable quantification of parasite growth.
An alternate approach to specifying a definitive threshold is to
apply the same types of threshold models which we have
developed here using all available data. Such an approach would
have three advantages. First, it would allow all the field samples to
be used, thus reducing the potential for bias in the SMT samples.
Second, it would allow the development of resistance to be
monitored over time by looking for changes in the threshold
duration and minimum EC50. Third, it can be used to look for
stage-specific drug action in current and new antimalarial drugs.
Similar patterns and threshold values were found for CQ,
amodiaquine and mefloquine, suggesting all of these drugs have
their main effect on ring stage P. vivax parasites. Such a
relationship was not observed for the other antimalarials
investigated (i.e., artesunate, lumefantrine, piperaquine and
pyronaridine). Differences between the stage specific activity of
each drug and its variation between parasite species may prove
highly informative in elucidating the mechanisms of drug action as
well as innate and acquired drug resistance. While it is always
possible to investigate stage-specific drug activity using carefully
planned laboratory experiments, as reported by Russell et al. [15],
the methodology presented here can identify stage specificity
through far less laborious means, and can use previously collated
results.
Our simulation of parasite development in the SMT and
subsequent estimate for the duration of each life cycle stage is the
first attempt to model parasite development times for P. vivax. It is
important to note that the estimates are relative to the parasite
development in the restricted conditions of the SMT control well
and may not represent the length of the life stages in vivo, or indeed
in potential in vitro culture. It should also be expected that the
estimated duration of the ring stage underestimates the true
duration due to the delay in obtaining the blood sample after
parasite rupture and establishing the SMT. More expansive
sampling over the first 24 hours of the assay would likely reduce
the confidence intervals of the estimated development times.
In summary, a threshold modelling approach was applied to
data from a modified SMT to investigate resistance to CQ in P.
vivax. We identified patterns which suggest a non-linear relation-
ship between drug susceptibility in the parasite and both the
duration of an assay and the proportion of ring stage parasites in
the initial sample, which signifies tolerance of late stage parasites to
CQ. Consequently, we recommend that P. vivax isolates should
Table 2. Parameter estimates for threshold modelling of the relationship between the proportion of rings samples at hour 0 and
CQ EC50 in P. vivax.
Parameter Estimate 95% Confidence Intervals P-value
Lower Upper
Threshold (c) 0.65 0.42 0.89 ,0.001
Change in EC50 when proportion of rings at hour 0,c (a) 21693.2 22470.7 29 15.7 ,0.001
Mean EC50 when proportion of rings at hour 0.c (b, in nmols/l) 139.69 27.49 286.87 0.065
doi:10.1371/journal.pntd.0001772.t002
Table 3. Comparison of the threshold points for amodiaquine, chloroquine and mefloquine, when analysing the relationship
between assay duration and EC50 in P. vivax.
Drug Threshold Estimate (c, hrs) 95% Confidence Intervals P-value
Lower Upper
Chloroquine 33.73 28.15 39.31 ,0.001
Amodiaquine 31.13 27.84 35.7 0.01
Mefloquine 39.14 32.94 45.34 ,0.001
doi:10.1371/journal.pntd.0001772.t003
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contain a minimum of 66% ring stage life cycle stages, and that
assay duration should exceed 34 hours to ensure this stage-specific
effect does not artificially inflate the reported EC50. More
conservative thresholds would require a minimum of 90% ring
stage parasites and a minimum assay duration of 40 hours. An
alternative approach would be to use the statistical methodology
which has been developed. For field researchers, this threshold
modelling approach will allow for increased confidence in the
reliability of resistance results. This approach also provides a novel
means of detecting stage-specific drug activity for new antimalar-
ials, as demonstrated by our analysis of the susceptibility to
amodiaquine and mefloquine.
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